Awards and Publications for Dr Ooi Wei Seong

General Professional Training (Medical Officer)
Federated Dublin Voluntary Hospitals Scheme (Jul 2000 to Jun 2002)
-St. Vincent’s University Hospital, Dublin, Ireland
-St. Michael’s Hospital, Dun Laoghaire, Ireland

Higher Professional Training (Registrar)
-St. Vincent’s University Hospital, Dublin, Ireland
Registrar in Medical Oncology (Jul 2002 to Jun 2004)
Research Fellow in Medical Oncology (Jul 2004 – Jun 2005)

Clinical and Research Fellowship in Medical Oncology
-Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada (Aug 2005 to Jun 2008)

Resident Physician in Medical Oncology
-Singapore General Hospital (Aug 2008-Oct 2009)

Advanced Specialist Training in Medical Oncology
-National Cancer Centre Singapore (Nov 2009-Nov 2012)

Associate Consultant in Medical Oncology
-National Cancer Centre Singapore (Nov 2012-Dec 2013)

Visiting Consultant in Medical Oncology
-KK Women’s and Children’s Hospital, Singapore (Nov 2012- Dec 2013)

Specialist in Medical Oncology
-Raffles Hospital (Jan 2014 – Jul 2015)

Visiting Consultant in Medical Oncology
-National Cancer Centre Singapore (Jan 2014 – Sep 2016)

RESEARCH & PUBLICATIONS

1. Prognostic Value of Transmittance Waveform Analysis may differ for ICU and General Medical Patients.
Hayden PJ, Ooi W, Collins B, Mc Carthy D, Murphy K.
Postal presentation at:
XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH). July 6-12, 2001

2. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
rown J, O’Leary M, Ooi WS
Oncologist. 2004;9 Suppl 2:24-32. Review.

3. Medical problems in patients with malignancy: case 3. Ulcerating cytomegalovirus bronchitis in a patient with relapsed non-Hodgkin's lymphoma.
Ooi WS, Crown JP. Clin Oncol. 2004 Oct 1;22(19):4022-3

4. Salvage treatment of patients with multiply-relapsed, unresectable, metastatic Germ-Cell Tumor (GCT), following failed multi-cycle, high-dose Chemotherapy (HDC): Durable remission is still possible.
Morris P, Ooi W, Wroblickey P, Duffy K, Donnellan P, Ballot J, Armstrong J, Thornhill J, Crown J.
J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S,

Part I of II (June 1 Supplement), 2005: 4790

5. Why do patients with metastatic breast cancer (MBC) continue to have bone destruction despite bisphosphonate (BP) use? A pathologic review.
WS. Ooi, C. Gainford, H. Kahn, M. Kalina, S. Popovic, G. Singh, M. Clemons.
Poster presentation at:
The Eighth and Valedictory Workshop on Bisphosphonates – From the Laboratory to the Patient. Davos, Switzerland.    Mar 22-24, 2006.
Clinical session, poster no.98.

6. Bisphosphonate use for metastatic breast cancer – Too much? Too little? Too late to start again?
Vanhuyse M. Gainford MC, Ooi W, Dranitsaris G, Clemons M.
Poster presentation at:
The Eighth and Valedictory Workshop on Bisphosphonates – From the Laboratory to the Patient. Davos, Switzerland.     Mar 22-24, 2006.
Clinical session, poster no.108.

7. Urinary n-telopeptide (NTX) predicts palliative pain response in metastatic breast cancer patients receiving second-line zoledronic acid.
G. Dranitsaris, M. Clemons, W. Ooi, D. Cole. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 679

8. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE. J Clin Oncol, 2006 Oct 20;24(30):4895-900. Epub 2006 Sep 25

9. Oral ibandronate provides significant palliative benefit in metastatic breast Cancer patients who have experienced bony progression or a skeletal related event (SRE) despite first-line bisphosphonate therapy.
Clemons M, Dranitsaris G, Ooi WS, Yogendran G, Cole DEC.
Poster presentation at:
29th Annual San Antonio Breast Cancer Symposium. Dec 14-17, 2006.
Poster Session III

10. Practices of Bone Mineral Density testing for osteoporosis in postmenopausal women following diagnosis and completion of primary treatment of breast cancer at Toronto Sunnybrook Regional Cancer Centre.
Ooi WS, Hawker G, Loblaw A, Beyenne J, Pritchard K.
Poster presentation at:
Canadian Association of Medical Oncologists (CAMO) 2007 Annual
Scientific Meeting. Apr 26, 2007.

11. Mechanisms of bone metastasis growth in patients with metastatic breast cancer: An exploratory study.
W.S. Ooi, S. Popovic, M. Kalina, H.Kahn, G.Singh, M.C. Gainford, M.Clemons.
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007: 1102

12. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.
O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S.
Anticancer Res. 2007 Jul-Aug;27(4B):2115-20.

13. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain.
Nan Soon Wong, Wei Seong Ooi, Kathleen I Pritchard. J Clin Oncol 2007 Aug;25(24):3787

14. Practices of Bone Mineral Density testing for osteoporosis in postmenopausal women following diagnosis and completion of primary treatment of breast cancer at Toronto Sunnybrook Regional Cancer Centre.
Ooi WS, Hawker G, Loblaw A, Beyenne J, Pritchard K.
Poster presentation at:
Canadian Oncology Winter Conference- Targeted Therapy & Chemotherapy in Oncology. Mar 6-9, 2008.

15. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M
Clin Oncol (R Coll Radiol). 2008 Dec;20(10):763-8. Epub 2008 Sep 27

16. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M, Ooi WS, Amir E, Popovic S, Kalina M, Singh G, Gainford MC, Clemons M.
Oncol Rep. 2009 May;21(5):1153-9

17. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.
Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M.
Cancer. 2010 Jan 15;115(2):284-91

18. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.
Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L. Br J Cancer. 2010 Mar 30;102(7):1157-62

19. A case of large B-cell intravascular lymphoma in the brain
Gan LP, Ooi WS, Lee HY, Ng WH. Surg Neurol Int. 2013 Jul 26;4:99